Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

ClinicalTrials.gov ID: NCT01228838

Public ClinicalTrials.gov record NCT01228838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN)

Study identification

NCT ID
NCT01228838
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NeurogesX
Industry
Enrollment
183 participants

Conditions and interventions

Interventions

  • NGX-1998 Drug
  • Placebo Liquid Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2010
Primary completion
Aug 31, 2011
Completion
Aug 31, 2011
Last update posted
Sep 9, 2012

2010 – 2011

United States locations

U.S. sites
35
U.S. states
24
U.S. cities
35
Facility City State ZIP Site status
NeurogesX Investigational Site Huntsville Alabama
NeurogesX Investigational Site Tucson Arizona
NeurogesX Investigational Site Irvine California
NeurogesX Investigational Site La Jolla California
NeurogesX Investigational Site Napa California
NeurogesX Investigational Site San Francisco California
NeurogesX Investigational Site Santa Monica California
NeurogesX Investigational Site New Port Richey Florida
NeurogesX Investigational Site North Palm Beach Florida
NeurogesX Investigational Site Sarasota Florida
NeurogesX Investigational Site St. Petersburg Florida
NeurogesX Investigational Site Marietta Georgia
NeurogesX Investigational Site Boise Idaho
NeurogesX Investigational Site Bloomington Illinois
NeurogesX Investigational Site West Des Moines Iowa
NeurogesX Investigational Site Kansas City Kansas
NeurogesX Investigational Site Lexington Kentucky
NeurogesX Investigational Site Shreveport Louisiana
NeurogesX Investigational Site Hyannis Massachusetts
NeurogesX Investigational Site Ann Arbor Michigan
NeurogesX Investigational Site Minneapolis Minnesota
NeurogesX Investigational Site Hattiesburg Mississippi
NeurogesX Investigational Site Albany New York
NeurogesX Investigational Site Rochester New York
NeurogesX Investigational Site Hickory North Carolina
NeurogesX Investigational Site Winston-Salem North Carolina
NeurogesX Investigational Site Portland Oregon
NeurogesX Investigational Site Altoona Pennsylvania
NeurogesX Investigational Site San Antonio Texas
NeurogesX Investigational Site Webster Texas
NeurogesX Investigational Site Salt Lake City Utah
NeurogesX Investigational Site Richmond Virginia
NeurogesX Investigational Site Seattle Washington
NeurogesX Investigational Site Wenatchee Washington
NeurogesX Investigational Site Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01228838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2012 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01228838 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →